11 Dec 2024
07:00 CET |
PHARMING GROUP |
Pharming announces positive topline data in pediatric clinical trial of leniolisib
|
20103015 Pharmaceuticals |
Products and services |
24 Oct 2024
07:00 CEST |
PHARMING GROUP |
Pharming Group reports third quarter 2024 financial results and provides business update
|
20103015 Pharmaceuticals |
Commercial results |
10 Oct 2024
08:00 CEST |
PHARMING GROUP |
Pharming Group to report third quarter 2024 financial results on October 24
|
20103015 Pharmaceuticals |
- |
10 Oct 2024
07:00 CEST |
PHARMING GROUP |
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
|
20103015 Pharmaceuticals |
Products and services |
26 Sep 2024
07:00 CEST |
PHARMING GROUP |
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
|
20103015 Pharmaceuticals |
Products and services |
01 Aug 2024
07:00 CEST |
PHARMING GROUP |
Pharming Group reports second quarter and first half 2024 financial results and provides business update
|
20103015 Pharmaceuticals |
Commercial results |
18 Jul 2024
08:00 CEST |
PHARMING GROUP |
Pharming Group to report second quarter and first half 2024 financial results on August 1
|
20103015 Pharmaceuticals |
Meetings / events |
03 Jun 2024
08:00 CEST |
PHARMING GROUP |
Pharming Group to participate in June investor conferences
|
20103015 Pharmaceuticals |
Meetings / events |
30 May 2024
22:44 CEST |
PHARMING GROUP |
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
|
20103015 Pharmaceuticals |
Products and services |
21 May 2024
17:30 CEST |
PHARMING GROUP |
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
20 May 2024
08:00 CEST |
PHARMING GROUP |
Pharming Group to participate in May investor conference
|
20103015 Pharmaceuticals |
Meetings / events |
15 May 2024
07:00 CEST |
PHARMING GROUP |
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
|
20103015 Pharmaceuticals |
Other financial transaction |
08 May 2024
07:00 CEST |
PHARMING GROUP |
Pharming Group reports first quarter 2024 financial results and provides business update
|
20103015 Pharmaceuticals |
Commercial results |
24 Apr 2024
08:00 CEST |
PHARMING GROUP |
Pharming Group to report first quarter 2024 financial results on May 8
|
20103015 Pharmaceuticals |
Meetings / events |
24 Apr 2024
07:00 CEST |
PHARMING GROUP |
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
|
20103015 Pharmaceuticals |
Other subject |
19 Apr 2024
18:43 CEST |
PHARMING GROUP |
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
|
20103015 Pharmaceuticals |
Other financial transaction |
18 Apr 2024
15:04 CEST |
PHARMING GROUP |
Pharming Group announces the placement of €100 million convertible bonds due 2029
|
20103015 Pharmaceuticals |
Other financial transaction |
18 Apr 2024
08:00 CEST |
PHARMING GROUP |
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
|
20103015 Pharmaceuticals |
Other financial transaction |
08 Apr 2024
07:00 CEST |
PHARMING GROUP |
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
|
20103015 Pharmaceuticals |
Other subject |
04 Apr 2024
08:30 CEST |
PHARMING GROUP |
Pharming Group announces the 2024 Annual General Meeting of Shareholders
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
04 Apr 2024
07:00 CEST |
PHARMING GROUP |
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
|
20103015 Pharmaceuticals |
Commercial results |
03 Apr 2024
08:00 CEST |
PHARMING GROUP |
Pharming Group to participate in April investor conferences
|
20103015 Pharmaceuticals |
Meetings / events |
14 Mar 2024
07:00 CET |
PHARMING GROUP |
Pharming Group reports fourth quarter and full year 2023 financial results
|
20103015 Pharmaceuticals |
Commercial results |
29 Feb 2024
08:00 CET |
PHARMING GROUP |
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
|
20103015 Pharmaceuticals |
Meetings / events |
08 Feb 2024
08:00 CET |
PHARMING GROUP |
Pharming Group to participate in February investor conferences
|
20103015 Pharmaceuticals |
Meetings / events |
08 Jan 2024
07:00 CET |
PHARMING GROUP |
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
|
20103015 Pharmaceuticals |
Commercial results |
13 Dec 2023
07:00 CET |
PHARMING GROUP |
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
|
20103015 Pharmaceuticals |
Other subject |
21 Nov 2023
07:00 CET |
PHARMING GROUP |
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
|
20103015 Pharmaceuticals |
Other subject |
10 Nov 2023
14:51 CET |
PHARMING GROUP |
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
|
20103015 Pharmaceuticals |
Other subject |
01 Nov 2023
08:00 CET |
PHARMING GROUP |
Pharming Group to participate in November investor conferences
|
20103015 Pharmaceuticals |
- |
26 Oct 2023
07:00 CEST |
PHARMING GROUP |
Pharming Group reports third quarter 2023 financial results
|
20103015 Pharmaceuticals |
Commercial results |
12 Oct 2023
08:00 CEST |
PHARMING GROUP |
Pharming Group to report third quarter 2023 financial results on October 26
|
20103015 Pharmaceuticals |
Meetings / events |
25 Sep 2023
16:00 CEST |
PHARMING GROUP |
Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |